Please assess the completion status of the following clinical trial:

Trial Title: A Study of Volociximab in Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~1. Must give written informed consent and any authorizations required by local law (e.g., Protected Health Information \[PHI\]).~2. Aged \>=18 years old at the time of informed consent.~3. Stage III and Stage IV unresectable melanoma with documented progression during or following the most recent prior melanoma therapy.~4. Must have failed at least 1 prior therapy for metastatic disease.~5. Must have at least 2 cutaneous, subcutaneous, or nodal metastases that are safely accessible for pre treatment and post treatment biopsies.~6. Must agree to pre-treatment and post-treatment biopsies of tumor lesions (subjects in Stage 1 only).~7. Must have at least 1 measurable target lesion for CT/MRI assessment, according to RECIST criteria.~8. ECOG Performance Status \<=1.~9. Acceptable laboratory results~10. Life expectancy \>=12 weeks.~11. Male subjects and female subjects of child bearing potential must be willing to practice effective contraception during the study and be willing and able to continue contraception for 4 months after last infusion of study treatment.~Exclusion Criteria~1. Subjects with any other active malignancy in addition to metastatic melanoma.~2. CNS metastases, unless stable for at least 2 months following definitive local therapy (surgery, stereotactic radiation). Subjects may not require treatment with steroids or anticonvulsants.~3. History of any other significant medical condition, including cardiovascular, pulmonary, neurologic, or autoimmune disease; active infections (e.g., bacterial or fungal); or a psychiatric condition within 6 months of Day 1~4. History of hepatitis B or C.~5. Known history of HIV infection or AIDS.~6. History of thromboembolic or cerebrovascular events, such as stroke, transient ischemic attack, deep vein thrombosis, or bleeding disorders within 12 months prior to Day 1.~7. Prior radiation therapy, chemotherapy, hormonal therapy, or immunotherapy for melanoma within 4 weeks prior to Day 1.~8. Previous exposure to volociximab.~9. Aspirin, high dose warfarin, or heparin use. (Note: Aspirin \<=81 mg/day, low-dose warfarin 1 mg/day or low-dose heparin for IV catheter patency is allowed.)~10. Major surgery within 4 weeks prior to Day 1.~11. Requirement for immunosuppression, and/or systemic steroid therapy.~12. Investigational therapies within 4 weeks prior to Day 1 or 4 half lives of the prior investigational drug (whichever is longer).~13. Known hypersensitivity to murine or chimeric antibodies.~14. Any condition that, in the opinion of the Investigator, makes the subject unsuitable for study participation.~15. Female subjects who are pregnant or currently breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Volociximab (Type: EXPERIMENTAL): Volociximab 15 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy